The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.

• Status: RECRUITING
• Trial end date: 2025-06-30

Summary

Study to evaluate the safety and tolerability of single ascending doses of brexpiprazole long-acting injection in healthy subjects/patients with schizophrenia.

• Phase: PHASE1

Details

• Lead Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.